fda stops tirzepatide says the weight-loss drug shortage is over Areas to Inject Tirzepatide: FDA-Approved

It is not allowed for human consumption, therapeutic use, or veterinary application

Source : NEJM SURMOUNT-1 Trial Over 90% achieved 5%+ weight loss 9 out of 10 participants lost at least 5% of their body weight using GLP-1 + GIP a powerful early milestone toward long-term success

TrimRx requires patients to report any gastrointestinal symptoms lasting more than 72 hours and conducts monthly check-ins during dose escalation to monitor tolerability and titration appropriateness

[6] Key findings included: [6] The L-citrulline + glutathione group experienced significant increases in lean mass compared to placebo after 4 weeks of resistance training